⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

March 1, 2026ESMO rare cancers.Open Access

291P Whole-body MRI screening for Li-Fraumeni syndrome: The Irish experience

A. Talbot Nathan Brady Hugo C. Temperley James F. Meaney DJ Gallagher

View Full Paper

Ask AI

Bookmark

Share

Key Points

The study aims to analyze the effectiveness of whole-body MRI in screening individuals for Li-Fraumeni syndrome.
Conducted a screening using whole-body MRI for individuals at risk of Li-Fraumeni syndrome.
Evaluated the occurrence and severity of adverse events related to pimi treatment.
Collected data on laboratory abnormalities and clinical symptoms during screening.
Identified manageable and reversible toxicity profiles related to pimi treatment.
Long-term use of pimi resulted in sustained antitumor activity.
Few treatment discontinuations were due to adverse events.

Implication

Analysis of whole-body MRI screening impacts outcomes in Li-Fraumeni syndrome, indicating effective safety monitoring.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Talbot et al. (2026) studied this question.

synapsesocial.com/papers/69b3aaa802a1e69014ccb71e https://doi.org/10.1016/j.esmorc.2026.100216

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1290P Sarcomatous transformation in germ cell tumors arises through early clonal divergence rather than linear progressionClinical Trial · 2026
2292P Exploring HER3; A potentially targetable biomarker in rare metaplastic breast cancersClinical Trial · 2026
3Longer-term safety of pimicotinib in tenosynovial giant cell tumor (TGCT): Integrated analysis of phase 1 and phase 3 MANEUVER trial data.Human Clinical Trial · 2026
4Adverse events and their management in patients with tenosynovial giant cell tumor (TGCT) treated with pimicotinib, after longer-term follow-up from the global phase 3 MANEUVER trial.Late-Phase Clinical Trial · 2026
5Effect of pimicotinib on tumor response and physical function (PF) by tumor location in patients with tenosynovial giant cell tumor (TGCT): Results from the phase 3 MANEUVER trial.RCT · 2026

More related papers

289P Manageable longer-term safety with the highly-selective colony stimulating factor-1 receptor (CSF-1R) inhibitor pimicotinib in patients with tenosynovial giant cell tumor (TGCT) in the global MANEUVER trial2026
CHAPTER-GIST-101: A phase I study of pimitespib combined with imatinib in patients with imatinib-refractory gastrointestinal stromal tumor.2024
Expert Perspectives on TGCT and the Outcomes of the Phase 3 MANEUVER Study of Pimicotinib Presented at ASCO and ESMO 2025: A Podcast Discussion2026

More from ESMO rare cancers.

Prolonged disease control with trabectedin in metastatic EWSR1::PATZ1 sarcoma: a case reportMon,
A case of mucinous adenocarcinoma of the prostate: pathological complete response achieved with intensity-modulated radiation therapyMon,